Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
CH0100191136
Tue, 30.04.2024
Relief Therapeutics Holding SA
Relief Therapeutics has published its Annual Report
GENEVA (APR. 30, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today published its Annual Report 2023 and provided a corporate update. [ … ]
Wed, 27.03.2024
Relief Therapeutics Holding SA
RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General MeetingRelief Therapeutics Calls Extraordinary General Meeting
Anticipated Board of Directors Overhaul
GENEVA (MAR. 27, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innova [ … ]
Fri, 22.03.2024
Relief Therapeutics Holding SA
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE®
GENEVA (MAR. 22, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare [ … ]
Wed, 28.02.2024
Relief Therapeutics Holding SA
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
3-year CHF 50 million capital commitment from GEM
Relief advances strategic transformation
GENEVA (FEB. 28, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment [ … ]
Tue, 05.12.2023
Relief Therapeutics Holding SA
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
GENEVA (DEC. 5, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet [ … ]
Wed, 22.11.2023
Relief Therapeutics Holding SA
Relief Therapeutics Announces CEO Transition
GENEVA (NOV. 22, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that its current chief executive officer (CEO) [ … ]
Tue, 10.10.2023
Relief Therapeutics Holding SA
Relief Therapeutics Announces that more than 400,000 of its ADRs are currently outstanding and that, as a result, the Company has achieved an Important NASDAQ Initial Listing Milestone
GENEVA (OCT. 10, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to deliverin [ … ]
Fri, 15.09.2023
Relief Therapeutics Holding SA
Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update
GENEVA (SEPT. 15, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today reported [ … ]
Fri, 01.09.2023
Relief Therapeutics Holding SA
Relief Therapeutics Holding SA
/ Key word(s): Conference
Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
01.09.2023 / 07:45 CET/CEST
Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
GENEVA (SEPT. 1, 2023) – [ … ]
Wed, 30.08.2023
Relief Therapeutics Holding SA
Ad hoc announcement pursuant to Art. 53 LR
Relief Therapeutics Announces New Exclusive Definitive License Agreement for
OLPRUVA™ (ACER-001) with Acer TherapeuticsAcer Therapeutics buys Relief Therapeutics’ stake in OLPRUVA™ worldwide, excluding geographical Europe, providing an upfront payment of $10 million in cash to Relief Therapeutics with [ … ]